CA1229553A - Pharmaceutical preparation for the treatment of hypertensive disease and myocardial infarction - Google Patents
Pharmaceutical preparation for the treatment of hypertensive disease and myocardial infarctionInfo
- Publication number
- CA1229553A CA1229553A CA000453725A CA453725A CA1229553A CA 1229553 A CA1229553 A CA 1229553A CA 000453725 A CA000453725 A CA 000453725A CA 453725 A CA453725 A CA 453725A CA 1229553 A CA1229553 A CA 1229553A
- Authority
- CA
- Canada
- Prior art keywords
- day
- changes
- pharmaceutical preparation
- animals
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 206010020772 Hypertension Diseases 0.000 title abstract description 11
- 208000010125 myocardial infarction Diseases 0.000 title abstract description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 59
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 22
- 206010028851 Necrosis Diseases 0.000 description 21
- 230000017074 necrotic cell death Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000004872 arterial blood pressure Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 230000008595 infiltration Effects 0.000 description 13
- 238000001764 infiltration Methods 0.000 description 13
- 210000002808 connective tissue Anatomy 0.000 description 10
- 229960001597 nifedipine Drugs 0.000 description 10
- 230000037390 scarring Effects 0.000 description 10
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 8
- 206010014950 Eosinophilia Diseases 0.000 description 7
- 241000282320 Panthera leo Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000001077 hypotensive effect Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940102884 adrenalin Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 101710200331 Cytochrome b-245 chaperone 1 Proteins 0.000 description 1
- 102100037186 Cytochrome b-245 chaperone 1 Human genes 0.000 description 1
- 101710119396 Cytochrome b-245 chaperone 1 homolog Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001505295 Eros Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FUHQFAMVYDIUKL-UHFFFAOYSA-N fox-7 Chemical compound NC(N)=C([N+]([O-])=O)[N+]([O-])=O FUHQFAMVYDIUKL-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 239000011440 grout Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000005332 obsidian Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU3593392 | 1983-05-18 | ||
| SU3593392 | 1983-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1229553A true CA1229553A (en) | 1987-11-24 |
Family
ID=21064187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000453725A Expired CA1229553A (en) | 1983-05-18 | 1984-05-07 | Pharmaceutical preparation for the treatment of hypertensive disease and myocardial infarction |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4568689A (enExample) |
| JP (1) | JPS59222416A (enExample) |
| CA (1) | CA1229553A (enExample) |
| DE (1) | DE3418651A1 (enExample) |
| FR (1) | FR2548899B1 (enExample) |
| GB (1) | GB2142533B (enExample) |
| IT (1) | IT1196109B (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2319278C2 (de) * | 1973-04-17 | 1986-02-20 | Bayer Ag, 5090 Leverkusen | Pharmazeutisches Mittel |
| US3974176A (en) * | 1973-08-16 | 1976-08-10 | Byk-Gulden Lomberg Chemische Fabrik Gmbh | Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them |
| LU71847A1 (enExample) * | 1975-02-14 | 1977-01-05 | ||
| SU747855A1 (ru) * | 1978-04-12 | 1980-07-15 | Ташкентский Ордена Трудового Красного Знамени Медицинский Институт | 3-Пиразолилметиловый эфир пропионовой кислоты, обладающий противовоспалительной активностью |
| GB2073740A (en) * | 1980-03-03 | 1981-10-21 | Wellcome Found | Pyrazolidinones |
-
1984
- 1984-05-07 CA CA000453725A patent/CA1229553A/en not_active Expired
- 1984-05-15 GB GB08412342A patent/GB2142533B/en not_active Expired
- 1984-05-16 IT IT20949/84A patent/IT1196109B/it active
- 1984-05-16 US US06/610,634 patent/US4568689A/en not_active Expired - Fee Related
- 1984-05-18 FR FR8407799A patent/FR2548899B1/fr not_active Expired
- 1984-05-18 JP JP59100328A patent/JPS59222416A/ja active Pending
- 1984-05-18 DE DE19843418651 patent/DE3418651A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3418651A1 (de) | 1984-11-22 |
| DE3418651C2 (enExample) | 1987-11-05 |
| GB2142533B (en) | 1987-03-04 |
| IT1196109B (it) | 1988-11-10 |
| GB8412342D0 (en) | 1984-06-20 |
| US4568689A (en) | 1986-02-04 |
| JPS59222416A (ja) | 1984-12-14 |
| IT8420949A0 (it) | 1984-05-16 |
| FR2548899B1 (fr) | 1989-01-06 |
| IT8420949A1 (it) | 1985-11-16 |
| FR2548899A1 (fr) | 1985-01-18 |
| GB2142533A (en) | 1985-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69321087T2 (de) | Alpha-aminoketon Derivate | |
| DE3586920T2 (de) | Benzopyranverbindungen zur verwendung auf das kardiovaskulaere system. | |
| DE2933441A1 (de) | Neue spiro-oxazolidindione und solche verbindungen enthaltende arzneimittel | |
| DE69624253T2 (de) | Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren | |
| EP1276476A2 (de) | Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen | |
| CA1229553A (en) | Pharmaceutical preparation for the treatment of hypertensive disease and myocardial infarction | |
| JPH0680629A (ja) | 心律動障害の治療のためのアンジオテンシンｉｉ受容体拮抗剤 | |
| Freis | Hypertensive crisis | |
| DE1940566B2 (de) | 1- (2-Nitrilophenoxy)-2-hydroxy-3äthylaminopropan, Verfahren zu dessen Herstellung und diese enthaltende Arzneimittel | |
| US3966978A (en) | 4-Biphenylacetic acid as an inhibitor of platelet aggregation | |
| DE3204732C2 (enExample) | ||
| Dodds | The pharmacological action and clinical use of drugs with a camphor-and coramine-like action | |
| CA1068607A (en) | 2-cyclopropanecarboxamido-5-halothiazole as anti-inflammatory agents | |
| DE3904795C2 (de) | Pharmazeutisches Präparat und dessen Verwendung | |
| WOLFF et al. | Analgesic Treatment in Acute Myocardial Infarction: A Double‐blind Comparison of Ketobemidone+ the Spasmolytic A29 (Ketogan®) and Morphine | |
| TW209167B (enExample) | ||
| US4173583A (en) | Diastereoisomers of 5-(1-hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide | |
| US20040106671A1 (en) | Remedies for vesical hyperesthesia | |
| DE3878494T2 (de) | Mittel gegen zuckerkrankheit. | |
| US3966960A (en) | 3-(4-Biphenylcarbonyl)propionic acid as an inhibitor of platelet aggregation | |
| US3998820A (en) | 10'-[ω-N-/1,4-diazabicyclo(4,m,o)-alkanyl/-acyl]-phenothiazines, their acidic addition salts and quaternary salts, process for producing same and use | |
| EP1150680B1 (de) | Verwendung von moxonidin zur behandlung nach herzinfarkt | |
| Blumenthal et al. | Initial clinical experience with a new peripheral vasodilator, PR-G-138-Cl, in hypertensive patients | |
| DE2308240C3 (de) | Oral oder parenteral verabreichbares antihypertensives Mittel | |
| SU819106A1 (ru) | 7-(2,3-Диоксипропил-1)-8-гидразино-ТЕОфиллиН, пРО Вл ющий гипОТЕНзиВНОЕдиуРЕТичЕСКОЕ и СОСудОСужиВАющЕЕдЕйСТВиЕ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |